Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
October 26 2023 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced a presentation highlighting the role of an
enzymatic approach to support RNA-based therapeutics manufacturing
at the TIDES Europe annual meeting taking place in Amsterdam,
Netherlands and virtually October 30-November 1, 2023.
During the presentation, Codexis will showcase
how engineered enzymes can complement traditional chemical
synthesis methods by addressing scalability, cost and waste
challenges associated with commercial-scale production. The Company
will also showcase its technical progress on its Enzyme-Catalyzed
Oligonucleotide (ECO) Synthesis™ technology platform, being
developed to enable an enzymatic route of nucleic acid synthesis.
The presentation will be held live and virtually on Wednesday,
November 1, 2023. The Company will make a video recap of the TIDES
Europe presentation available on its website following the
conclusion of the meeting.
Presentation Details
Title: Revolutionizing Nucleic Acid Synthesis
with Engineered EnzymesDate: Wednesday, November
1, 2023Time: 1:35 pm – 2:05 pm Central European
Time (CET) Location: RAI Amsterdam, Amsterdam,
Netherlands
About the ECO Synthesis™
Platform Ribonucleic acid (RNA) as a therapeutic modality
has gained tremendous traction in recent years with the growing
number of messenger RNA (mRNA) vaccines and small interfering RNA
(siRNA) candidates advancing in clinical studies. However,
large-scale production of RNAi therapeutics using traditional
chemical synthesis faces complex challenges in nucleic acids
quality and quantity, as well as overall economics. With over 450
RNA interference (RNAi) therapies currently in clinical
development, including more than 40 assets in Phase 2 and Phase 3
clinical trials targeting disease indications impacting millions of
patients, RNAi therapeutic demand is projected to outpace current
production capabilities by the end of the decade. Codexis’
proprietary ECO Synthesis™ technology platform is being designed to
address these scalability and cost limitations by potentially
enabling the commercial-scale manufacture of RNAi therapeutics
through an enzymatic route. The Company is on track to demonstrate
gram-scale synthesis by the end of 2023, where it will demonstrate
the preparative-scale manufacture of an oligonucleotide, composed
of the modified nucleotide building blocks typically used in RNAi
therapeutics, under process-like conditions.
About CodexisCodexis is a
leading enzyme engineering company leveraging its proprietary
CodeEvolver® technology platform to discover, develop and enhance
novel, high-performance enzymes and other classes of proteins.
Codexis enzymes solve for real-world challenges associated with
small molecule pharmaceuticals manufacturing and nucleic acid
synthesis. The Company is currently developing its proprietary ECO
Synthesis™ platform to enable the scaled manufacture of RNAi
therapeutics through an enzymatic route. Codexis’ unique enzymes
can drive improvements such as higher yields, reduced energy usage
and waste generation, improved efficiency in manufacturing and
greater sensitivity in genomic and diagnostic applications. For
more information, visit https://www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. In some cases, you can identify
forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “suggest,” “target,” “on track,” “will,” “would”
and other similar expressions that are predictions of or indicate
future events and future trends, or the negative of these terms or
other comparable terminology. To the extent that statements
contained in this press release are not descriptions of historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management, including, but not limited
to, the ability of engineered enzymes to complement traditional
chemical syntesis; the Company’s technical progress on its ECO
Synthesis™ platform, as well as its potential to create value for
Codexis and its customers by enabling commercial-scale manufacture
of RNAi therapeutics; whether a significant market for RNAi
therapeutics will develop; and whether and if Codexis is able to
demonstrate gram-scale synthesis of its ECO Synthesis™ technology
by the end of 2023. You should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual
results. Factors that could materially affect actual results
include, among others: Codexis’ dependence on its licensees and
collaborators; Codexis’ ability to successfully develop its ECO
Synthesis™ technology; if any of its collaborators terminate their
development programs under their respective license agreements with
Codexis; Codexis may need additional capital in the future in order
to expand its business; Codexis’ dependence on a limited number of
products and customers, and potential adverse effects to Codexis’
business if its customers’ products are not received well in the
markets; whether the end markets for Codexis’ customers’ products
develop and remain viable; if Codexis is unable to develop and
commercialize new products for its target markets; if competitors
and potential competitors who have greater resources and experience
than Codexis develop products and technologies that make Codexis’
products and technologies obsolete; and market and economic
conditions may negatively impact Codexis business, financial
condition and share price. Additional information about factors
that could materially affect actual results can be found in
Codexis’ Annual Report on Form 10-K for the year ended December 31,
2022 filed with the Securities and Exchange Commission (“SEC”) on
February 27, 2023 and in Codexis’ Quarterly Report on Form 10-Q for
the quarter ended June 30, 2023 filed with the SEC on August 3,
2023, including under the caption “Risk Factors,” and in Codexis’
other periodic reports filed with the SEC. Codexis expressly
disclaims any intent or obligation to update these forward-looking
statements, except as required by law.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024